vs
Embecta Corp.（EMBC）与Piedmont Realty Trust, Inc.（PDM）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是Piedmont Realty Trust, Inc.的1.8倍（$261.2M vs $143.3M），Embecta Corp.净利率更高（16.9% vs -31.4%，领先48.3%），Piedmont Realty Trust, Inc.同比增速更快（0.4% vs -0.3%），过去两年Piedmont Realty Trust, Inc.的营收复合增速更高（0.0% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Piedmont Realty Trust是一家公开上市的房地产投资信托（REIT），主要持有、运营和投资美国高增长大都会区的优质写字楼资产，服务科技、专业服务、医疗等多个行业的企业租户，通过战略资产管理和投资组合优化为利益相关方提供稳定长期回报。
EMBC vs PDM — 直观对比
营收规模更大
EMBC
是对方的1.8倍
$143.3M
营收增速更快
PDM
高出0.7%
-0.3%
净利率更高
EMBC
高出48.3%
-31.4%
两年增速更快
PDM
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $143.3M |
| 净利润 | $44.1M | $-45.0M |
| 毛利率 | 61.9% | — |
| 营业利润率 | 31.9% | — |
| 净利率 | 16.9% | -31.4% |
| 营收同比 | -0.3% | 0.4% |
| 净利润同比 | — | -27.9% |
| 每股收益（稀释后） | $0.74 | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCPDM
| Q1 26 | — | $143.3M | ||
| Q4 25 | $261.2M | $142.9M | ||
| Q3 25 | $264.0M | $139.2M | ||
| Q2 25 | $295.5M | $140.3M | ||
| Q1 25 | $259.0M | $142.7M | ||
| Q4 24 | $261.9M | $143.2M | ||
| Q3 24 | $286.1M | $139.3M | ||
| Q2 24 | $272.5M | $143.3M |
净利润EMBCPDM
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $44.1M | $-43.2M | ||
| Q3 25 | $26.4M | $-13.5M | ||
| Q2 25 | $45.5M | $-16.8M | ||
| Q1 25 | $23.5M | $-10.1M | ||
| Q4 24 | $0 | $-30.0M | ||
| Q3 24 | $14.6M | $-11.5M | ||
| Q2 24 | $14.7M | $-9.8M |
毛利率EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | 31.9% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 31.8% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 11.0% | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 20.5% | — |
净利率EMBCPDM
| Q1 26 | — | -31.4% | ||
| Q4 25 | 16.9% | -30.3% | ||
| Q3 25 | 10.0% | -9.7% | ||
| Q2 25 | 15.4% | -12.0% | ||
| Q1 25 | 9.1% | -7.1% | ||
| Q4 24 | — | -20.9% | ||
| Q3 24 | 5.1% | -8.3% | ||
| Q2 24 | 5.4% | -6.8% |
每股收益（稀释后）EMBCPDM
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $0.74 | $-0.34 | ||
| Q3 25 | $0.44 | $-0.11 | ||
| Q2 25 | $0.78 | $-0.14 | ||
| Q1 25 | $0.40 | $-0.08 | ||
| Q4 24 | $0.00 | $-0.25 | ||
| Q3 24 | $0.24 | $-0.09 | ||
| Q2 24 | $0.25 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $2.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $1.5B |
| 总资产 | $1.1B | $4.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCPDM
| Q1 26 | — | $2.3M | ||
| Q4 25 | $201.3M | $731.0K | ||
| Q3 25 | $225.5M | $3.0M | ||
| Q2 25 | $230.6M | $3.3M | ||
| Q1 25 | $209.3M | $2.9M | ||
| Q4 24 | $210.0M | $109.6M | ||
| Q3 24 | $267.5M | $133.6M | ||
| Q2 24 | $275.1M | $138.5M |
总债务EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益EMBCPDM
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-613.1M | $1.5B | ||
| Q3 25 | $-650.6M | $1.5B | ||
| Q2 25 | $-669.6M | $1.5B | ||
| Q1 25 | $-736.2M | $1.6B | ||
| Q4 24 | $-768.8M | $1.6B | ||
| Q3 24 | $-738.3M | $1.6B | ||
| Q2 24 | $-763.7M | $1.7B |
总资产EMBCPDM
| Q1 26 | — | $4.0B | ||
| Q4 25 | $1.1B | $4.0B | ||
| Q3 25 | $1.1B | $4.0B | ||
| Q2 25 | $1.2B | $4.0B | ||
| Q1 25 | $1.1B | $4.0B | ||
| Q4 24 | $1.1B | $4.1B | ||
| Q3 24 | $1.3B | $4.1B | ||
| Q2 24 | $1.3B | $4.2B |
负债/权益比EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | — |
| 自由现金流经营现金流 - 资本支出 | $16.6M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 0.2% | 110.3% |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | $17.2M | $140.6M | ||
| Q3 25 | $84.0M | $35.8M | ||
| Q2 25 | $81.2M | $50.1M | ||
| Q1 25 | $31.8M | $3.7M | ||
| Q4 24 | $-5.3M | $198.1M | ||
| Q3 24 | $26.6M | $42.9M | ||
| Q2 24 | $-2.1M | $66.8M |
自由现金流EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | $16.6M | — | ||
| Q3 25 | $76.7M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $31.7M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-11.8M | — |
自由现金流率EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 27.3% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.3% | — |
资本支出强度EMBCPDM
| Q1 26 | — | 110.3% | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 3.6% | — |
现金转化率EMBCPDM
| Q1 26 | — | — | ||
| Q4 25 | 0.39× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
PDM
暂无分部数据
